ArticleHuman cell2022
Long noncoding RNA SNHG3 promotes malignant phenotypes in cervical cancer cells via association with YAP1.
Article in Human cell, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.
- High SNHG expression may contribute to poor cervical cancer prognosis, based on systematic reviews and meta-analyses.BMC cancer · 2025Pooled it
- LncRNA SNHG3: a potential biomarker for human diseases.Frontiers in cell and developmental biology · 2026Review
- Recent advancement in inflammatory biomarkers for cervical cancer diagnosis and therapy.Frontiers in oncology · 2026Review
- Identification of a cancer driver gene-associated lncRNA signature for prognostic prediction and immune response evaluation in clear cell renal cell carcinoma.Translational cancer research · 2024Article
- SNHG3/WISP2 Axis Promotes Hela Cell Migration and InvasionCancer genomics & proteomics · 2023Article
- The interplay between noncoding RNA and YAP/TAZ signaling in cancers: molecular functions and mechanisms.Journal of experimental & clinical cancer research : CR · 2022Review
- Small nucleolar RNA host gene 3 functions as a novel biomarker in liver cancer and other tumour progression.World journal of gastroenterology · 2022Review
- Review
- Identification of m6A-Related lncRNA to Predict the Prognosis of Patients with Hepatocellular Carcinoma.BioMed research international · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Long non-coding RNA (LncRNA) Small Nucleolar RNA Host Gene 3 (SNHG3) is involved in the occurrence and development of various cancers. However, the exact function and mechanism of SNHG3 in cervical cancer (CC) are still unclear. In this context, we identified a significant increase of SNHG3 expression in CC tissues. Upregulation of SNHG3 expression was associated with advanced FIGO stage and metastasis, and indicated poor overall survival of the CC patients. Functionally, SNHG3 enhanced the proliferation, migration and invasion of CC cells in vitro, and facilitated CC growth in vivo. Further investigation uncovered that SNHG3 interacted with oncoprotein YAP1, thus suppressing its degradation. Additionally, SNHG3 modulated the transcription of several target genes of YAP1. The oncogenic role of SNHG3 was partially attributable to YAP1. Taken together, our research revealed the prognostic and functional roles for SNHG3 in CC, suggesting that SNHG3 could serve as a biomarker for prognosis and a therapeutic target for CC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.